JP2015508774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508774A5 JP2015508774A5 JP2014557754A JP2014557754A JP2015508774A5 JP 2015508774 A5 JP2015508774 A5 JP 2015508774A5 JP 2014557754 A JP2014557754 A JP 2014557754A JP 2014557754 A JP2014557754 A JP 2014557754A JP 2015508774 A5 JP2015508774 A5 JP 2015508774A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aqueous
- composition according
- treatment
- antibody pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 238000011282 treatment Methods 0.000 claims 22
- 208000027866 inflammatory disease Diseases 0.000 claims 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 6
- 239000000600 sorbitol Substances 0.000 claims 6
- 229920000136 polysorbate Polymers 0.000 claims 5
- 229950008882 polysorbate Drugs 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 101710145634 Antigen 1 Proteins 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000694440 Colpidium aqueous Species 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000004012 Tofacitinib Substances 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229960001350 tofacitinib Drugs 0.000 claims 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261599827P | 2012-02-16 | 2012-02-16 | |
| US61/599,827 | 2012-02-16 | ||
| PCT/US2013/026034 WO2013123114A2 (en) | 2012-02-16 | 2013-02-14 | Antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097486A Division JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508774A JP2015508774A (ja) | 2015-03-23 |
| JP2015508774A5 true JP2015508774A5 (enExample) | 2016-03-24 |
| JP6345123B2 JP6345123B2 (ja) | 2018-06-20 |
Family
ID=47997774
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557754A Expired - Fee Related JP6345123B2 (ja) | 2012-02-16 | 2013-02-14 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
| JP2018097486A Active JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097486A Active JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10316095B2 (enExample) |
| EP (1) | EP2814468B1 (enExample) |
| JP (2) | JP6345123B2 (enExample) |
| CN (1) | CN104271122A (enExample) |
| AU (2) | AU2013221635B2 (enExample) |
| CA (1) | CA2864539C (enExample) |
| ES (1) | ES2732243T3 (enExample) |
| IL (1) | IL233976B (enExample) |
| MX (1) | MX370199B (enExample) |
| NZ (1) | NZ629204A (enExample) |
| WO (1) | WO2013123114A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2557768T3 (es) | 1999-06-01 | 2016-01-28 | Biogen Ma Inc. | Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios |
| KR100927670B1 (ko) | 2001-04-13 | 2009-11-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｖｌａ-1에 대한 항체들 |
| PL3459564T3 (pl) | 2010-01-06 | 2022-04-19 | Takeda Pharmaceutical Company Limited | Białka wiążące kalikreinę osocza |
| KR102502293B1 (ko) | 2011-01-06 | 2023-02-21 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| US10316095B2 (en) * | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| EP3594244A1 (en) | 2013-03-15 | 2020-01-15 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| KR20220107077A (ko) | 2014-01-21 | 2022-08-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| JP2017531446A (ja) * | 2014-09-29 | 2017-10-26 | クック・ジェネラル・バイオテクノロジー・エルエルシー | 細胞懸濁液中のトレハロースの使用 |
| MX391067B (es) | 2014-10-01 | 2025-03-21 | Eagle Biologics Inc | Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad. |
| US20160367180A1 (en) * | 2015-06-17 | 2016-12-22 | Obsevera, Inc. | Apparatus and method of conducting medical evaluation of add/adhd |
| CA2998716A1 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| KR20250139401A (ko) | 2015-12-11 | 2025-09-23 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도 |
| MX2018011169A (es) * | 2016-03-14 | 2018-12-06 | Millennium Pharm Inc | Metodo para prevenir la enfermedad del injerto contra huesped. |
| BR112018075785A2 (pt) * | 2016-06-16 | 2019-04-02 | Janssen Vaccines & Prevention B.V. | formulação de vacina para o hiv |
| CR20180599A (es) * | 2016-06-30 | 2019-04-09 | Celltrion Inc | Preparación farmacéutica líquida estable |
| WO2019018688A1 (en) * | 2017-07-20 | 2019-01-24 | The University Of Virginia Patent Foundation | METHODS OF TREATING OR PREVENTING A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM |
| CN112236445A (zh) * | 2017-12-14 | 2021-01-15 | 芝加哥大学 | 用基因工程化的巨噬细胞治疗纤维化 |
| CN111787948A (zh) * | 2018-02-09 | 2020-10-16 | 健玛保 | 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途 |
| EP3911363A1 (en) * | 2019-01-14 | 2021-11-24 | University of Virginia Patent Foundation | Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury |
| MA55750A (fr) * | 2019-04-23 | 2022-03-02 | Sanofi Sa | Formulations d'anticorps stables et à faible viscosité et leurs utilisations |
| UA128416C2 (uk) * | 2019-08-15 | 2024-07-03 | Генмаб А/С | Фармацевтичні композиції, які містять біспецифічні антитіла проти cd3 і cd20, та їх застосування |
| CA3167336A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| CN115916166A (zh) | 2020-05-08 | 2023-04-04 | 健玛保 | 针对cd3和cd20的双特异性抗体 |
| JP2023542289A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| MX2023002544A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para tratar linfoma folicular. |
| EP4210744A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| AU2021342342A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia |
| CA3218343A1 (en) * | 2021-05-12 | 2022-11-17 | Anaptysbio, Inc. | Antibody composition |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5391481A (en) | 1990-08-31 | 1995-02-21 | The Trustees Of Columbia University | Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2127462C (en) | 1992-01-13 | 1999-03-23 | Roy R. Lobb | Treatment for asthma |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| EP0678122B1 (en) | 1993-01-12 | 1999-07-28 | Biogen, Inc. | Recombinant anti-vla4 antibody molecules |
| ES2114183T5 (es) | 1993-02-09 | 2006-06-16 | Biogen Idec Ma, Inc. | Anticuerpo para el tratamiento de la diabetes dependiente de la insulina. |
| US6111598A (en) | 1993-11-12 | 2000-08-29 | Peveo, Inc. | System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| PT804237E (pt) | 1994-01-25 | 2006-10-31 | Elan Pharm Inc | Anticorpos humanizados contra a molecula de adesao leucocitaria vla-4 |
| DK0759302T3 (da) | 1994-04-26 | 2000-11-13 | Kanebo Ltd | Middel mod rheumatoid arthritis |
| JPH08131185A (ja) | 1994-11-14 | 1996-05-28 | Sumitomo Electric Ind Ltd | マウスｖｌａ−１分子に対するモノクローナル抗体 |
| JPH08160972A (ja) | 1994-12-01 | 1996-06-21 | Sega Enterp Ltd | エフェクト制御方法、制御装置およびこれを利用したカラオケ装置 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9516399D0 (en) | 1995-08-10 | 1995-10-11 | Camelot Superabsorbents Ltd | Process for the production of water-absorbing compositions |
| DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| WO1997007671A1 (en) | 1995-08-29 | 1997-03-06 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for constructing the same |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| GB9519667D0 (en) | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US6127524A (en) | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| JP2002516287A (ja) | 1998-05-22 | 2002-06-04 | ボーイズ タウン ナショナル リサーチ ホスピタル | α１β１インテグリンレセプターインヒビターおよびＩＧＦ−β１インヒビターの腎臓病の治療における使用 |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| AU751157B2 (en) | 1998-10-06 | 2002-08-08 | Biogen Idec Ma Inc. | Crystals of the alpha 1 beta 1 integrin I-domain and their use |
| TR200200027T2 (tr) | 1999-04-22 | 2002-07-22 | Biogen, Inc. | İntergrin alfa-4 alt-biriminin bir antagonisti kullanılarak fibrozun tedavisi. |
| ES2557768T3 (es) | 1999-06-01 | 2016-01-28 | Biogen Ma Inc. | Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios |
| WO2000078221A1 (de) | 1999-06-17 | 2000-12-28 | Kai Desinger | Chirurgische sonde zur minimal invasiven gewebeentnahme |
| WO2001073444A2 (en) | 2000-03-28 | 2001-10-04 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| DE10028402A1 (de) | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| US7153944B2 (en) | 2000-07-31 | 2006-12-26 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
| KR100927670B1 (ko) | 2001-04-13 | 2009-11-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｖｌａ-1에 대한 항체들 |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| AU2003215298A1 (en) | 2002-02-14 | 2003-09-04 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
| CA2494310A1 (en) | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US20040208870A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| CA2512174A1 (en) * | 2003-01-30 | 2004-08-12 | Christian B. Allan | Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof |
| WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
| WO2005016883A2 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Acrylamide derivatives as vla-1 integrin antagonists and uses thereof |
| US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2006133286A2 (en) | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| US10119979B2 (en) * | 2006-05-25 | 2018-11-06 | Biogen Ma Inc. | Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies |
| US7626243B2 (en) | 2006-08-04 | 2009-12-01 | Advanced Analogic Technologies, Inc. | ESD protection for bipolar-CMOS-DMOS integrated circuit devices |
| EP2170390B1 (en) * | 2007-06-14 | 2018-11-07 | Biogen MA Inc. | Natalizumab antibody formulations |
| JP4951596B2 (ja) | 2008-07-31 | 2012-06-13 | 株式会社日立製作所 | 冷却システム及び電子装置 |
| CN102202655B (zh) * | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| CN102770158B (zh) * | 2009-12-21 | 2016-10-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| CA2794929C (en) * | 2010-03-01 | 2018-06-05 | Progenics Pharmaceuticals, Inc. | Concentrated protein formulations and uses thereof |
| AU2011257219B2 (en) * | 2010-05-28 | 2014-12-04 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| US20140017261A1 (en) | 2011-02-03 | 2014-01-16 | Mark Totoritis | Selection and treatment of subjects |
| JP5662565B2 (ja) | 2012-01-11 | 2015-02-04 | パナソニックＩｐマネジメント株式会社 | 圧接型半導体装置及びその製造方法 |
| US10316095B2 (en) | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
-
2013
- 2013-02-14 US US13/766,966 patent/US10316095B2/en active Active
- 2013-02-14 US US14/379,095 patent/US10160808B2/en active Active
- 2013-02-14 ES ES13711986T patent/ES2732243T3/es active Active
- 2013-02-14 MX MX2014009755A patent/MX370199B/es active IP Right Grant
- 2013-02-14 JP JP2014557754A patent/JP6345123B2/ja not_active Expired - Fee Related
- 2013-02-14 NZ NZ629204A patent/NZ629204A/en not_active IP Right Cessation
- 2013-02-14 CA CA2864539A patent/CA2864539C/en active Active
- 2013-02-14 CN CN201380019988.XA patent/CN104271122A/zh active Pending
- 2013-02-14 AU AU2013221635A patent/AU2013221635B2/en not_active Ceased
- 2013-02-14 EP EP13711986.3A patent/EP2814468B1/en active Active
- 2013-02-14 WO PCT/US2013/026034 patent/WO2013123114A2/en not_active Ceased
- 2013-08-30 US US14/015,039 patent/US20140010827A1/en not_active Abandoned
-
2014
- 2014-08-06 IL IL233976A patent/IL233976B/en active IP Right Grant
-
2017
- 2017-11-22 AU AU2017265049A patent/AU2017265049B2/en not_active Ceased
-
2018
- 2018-05-22 JP JP2018097486A patent/JP6759276B2/ja active Active
- 2018-12-20 US US16/227,564 patent/US20190194331A1/en not_active Abandoned
-
2019
- 2019-04-24 US US16/393,171 patent/US20190338036A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508774A5 (enExample) | ||
| JP2015519382A5 (enExample) | ||
| US11999777B2 (en) | Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies | |
| JP2015157821A5 (enExample) | ||
| FI3209681T3 (fi) | Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä | |
| JP2014530226A5 (enExample) | ||
| JP2010529026A5 (enExample) | ||
| EA201200490A1 (ru) | Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения | |
| JP2019527678A5 (enExample) | ||
| JP2013543505A5 (enExample) | ||
| JP7101479B2 (ja) | 関節リウマチ患者の健康に関連した生活の質を改善するための組成物 | |
| JP2018515493A5 (enExample) | ||
| JP2016516074A5 (enExample) | ||
| FI3294345T3 (fi) | Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi | |
| JP2018509388A5 (enExample) | ||
| JP2019507775A5 (enExample) | ||
| JP2021505620A5 (enExample) | ||
| JP2015172060A5 (enExample) | ||
| Josselin-Mahr et al. | Efficacy of imatinib mesylate in a case of Churg–Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase? | |
| JP2017524675A5 (enExample) | ||
| Samad et al. | Intracerebral coinfection with Burkholderia pseudomallei and Cryptococcus neoformans in a patient with systemic lupus erythematosus | |
| CN116327925B (zh) | 一种抗狂犬病毒人源抗体的组合制剂及应用 | |
| CN103341163B (zh) | 狂犬病、破伤风双效马抗血清及其制备方法 | |
| CN104096229A (zh) | 甘氨酸锌佐剂及含甘氨酸锌佐剂的疫苗 | |
| CN102584943A (zh) | 一种血管平滑肌l型钙离子通道免疫原性肽段及其用途 |